Humacyte, Inc.

NasdaqGS:HUMA Stock Report

Market Cap: US$168.0m

Humacyte Future Growth

Future criteria checks 2/6

Humacyte is forecast to grow earnings and revenue by 61.1% and 62.3% per annum respectively while EPS is expected to grow by 65.7% per annum.

Key information

61.1%

Earnings growth rate

65.73%

EPS growth rate

Biotechs earnings growth27.2%
Revenue growth rate62.3%
Future return on equityn/a
Analyst coverage

Low

Last updated13 Aug 2026

Recent future growth updates

Recent updates

Narrative Update • Jul 24

HUMA: V012 Phase 3 Data Will Drive Dialysis Access Opportunity

Humacyte's updated analyst price target of $4.00, along with shifts in fair value and key assumptions such as discount rate, revenue growth, profit margin, and future P/E, reflects analysts' response to recent positive V012 Phase 3 interim data, evolving indication expansion expectations, and refreshed long term revenue projections across dialysis and vascular applications. Analyst Commentary Recent research coverage on Humacyte highlights a mix of optimism around the V012 Phase 3 interim data, expectations for regulatory progress, and ongoing adjustments to revenue and indication assumptions.
Narrative Update • Jul 10

HUMA: V012 Phase 3 Dialysis Data Will Drive Future Repricing

Humacyte's updated analyst price targets, which now range from $1.25 to $4.00, reflect mixed revisions as analysts weigh positive interim V012 data and potential AV access indication expansion against updated assumptions for growth, profitability, and future P/E expectations. Analyst Commentary on Humacyte Recent street research on Humacyte reflects a wide range of expectations, with some analysts trimming price targets even as they acknowledge positive interim V012 data and potential indication expansion in dialysis access.
Narrative Update • Jun 26

HUMA: V012 Dialysis Data Will Shape Future Indication Expansion Prospects

Analysts have reset Humacyte’s fair value estimate from $7.86 to $2.05, citing updated assumptions on growth, margins, and long term P/E in light of recent price target revisions that reflect both encouraging V012 data and moderated expectations for the company’s acellular vessel portfolio. Analyst Commentary Recent Street research on Humacyte highlights mixed views, with some analysts leaning optimistic on the acellular vessel opportunity and others resetting expectations, which collectively helps explain the lower fair value estimate.
Seeking Alpha • Feb 09

Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist

Summary Humacyte, Inc. remains rated Hold despite a DoD funding catalyst revealed today, as commercial traction for Symvess is not yet proven. Symvess is the only FDA-approved human-derived bioengineered blood vessel, but Q3 revenue was just $700k, and uptake remains limited. HUMA's funding runway is constrained, with recent capital raises offset by high R&D spending; further dilution or cost cuts may be needed. Key 2026 catalysts are dialysis data readouts and BLA submissions, not the recent DoD news, given ongoing risks and modest near-term sales. Read the full article on Seeking Alpha
Analysis Article • Sep 19

Here's Why Humacyte (NASDAQ:HUMA) Can Afford Some Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • May 21

Is Humacyte (NASDAQ:HUMA) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Mar 24

Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade)

Summary Humacyte's stock has dropped 29% since December, despite FDA approval of Symvess. Symvess faces slow adoption due to the need for long-term outcomes data. Humacyte's financial health is precarious, with high operating expenses and a cash runway extending only into late 2025, raising concerns about future dilution. Given these challenges, I downgrade HUMA to "Sell," as achieving a return on investment for Symvess seems unlikely without significant financial strain. Read the full article on Seeking Alpha
Seeking Alpha • Jan 08

Humacyte: Expect A Slow Launch, But Vascular Trauma Indication Is Just A Beginning

Summary Humacyte, Inc. arrived on the Nasdaq in 2021 via a SPAC deal and reappeared on my radar after the Symvess approval in vascular trauma repair. Platform enabling off-the-shelf bioengineered tissues could transform the field of regenerative medicine. There's a large addressable market across 3 lead indications alone (trauma, dialysis & PAD) + significant optionality for more complex projects (i.e., biovascular pancreas in diabetes). Key concerns include slow launch out of the gate, continued cash burn & dilution, competition, and manufacturing capacity. My Action Plan: I remain on the sidelines for HUMA stock and will continue to monitor launch metrics as well as pipeline progress. Read the full article on Seeking Alpha
Seeking Alpha • Dec 23

Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)

Summary Humacyte stock has dropped 46% since July, mainly due to FDA review delays and mixed Phase 3 trial results for their ATEVs in hemodialysis. Despite FDA approval of Symvess for vascular trauma, its market potential is limited, and adoption is expected to be slow and costly. Phase 3 trial data for ATEVs in hemodialysis patients showed higher thrombosis and infection rates, raising concerns about its safety and efficacy. Humacyte's financial situation remains precarious, with high operating expenses and potential ongoing dilution, leading to a downgrade on HUMA stock from "buy" to "hold". Read the full article on Seeking Alpha
Seeking Alpha • Dec 14

Humacyte: FDA Waiting Game Bleeding Company Dry

Summary Humacyte's innovative ATEV technology shows promise but faces delays in FDA approval, initially expected in Aug, causing financial strain and uncertainty about its market potential. Despite strong clinical data, the FDA's postponement of the ATEV approval has left Humacyte in a precarious financial position, forcing it to raise ~$45m since August. The lack of a clear FDA timeline creates significant risk for investors, leading to a downgrade from "buy" to "hold" due to potential further delays. The market opportunity for ATEVs remains uncertain, questioning whether Humacyte stock can achieve significant upside even if FDA approval is granted. Read the full article on Seeking Alpha
Seeking Alpha • Sep 24

Humacyte: Navigating The FDA Uncertainty And ATEV's Potential

Summary Humacyte’s acellular tissue engineered vessel (ATEV) shows promise in trauma and dialysis, with positive clinical trial results and potential FDA approval by year-end. Despite FDA delays, Humacyte remains optimistic but faces financial instability, with only $43.6 million in cash, supporting operations for 1.5 quarters. HUMA stock is rated as a moderate "Buy" for high-risk tolerant investors, given the potential for FDA approval and significant market capture in trauma. Risks include potential FDA rejection, financial distress, and management's recent share sales, which warrant cautious investment consideration. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGS:HUMA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028111-17N/AN/A4
12/31/202722-68N/A-375
12/31/20263-95N/A-784
6/30/20262-97-98-97N/A
3/31/20262-95-102-102N/A
12/31/20252-41-106-105N/A
9/30/20252-37-106-105N/A
6/30/20251-59-106-104N/A
3/31/20251-78-101-99N/A
12/31/2024N/A-149-100-98N/A
9/30/2024N/A-153-92-91N/A
6/30/2024N/A-140-82-81N/A
3/31/2024N/A-106-84-82N/A
12/31/2023N/A-111-76-73N/A
9/30/2023N/A-89-76-73N/A
6/30/20230-89-80-77N/A
3/31/20231-29-73-71N/A
12/31/20222-12-72-71N/A
9/30/2022234-74-74N/A
6/30/2022228-88-87N/A
3/31/20221-26-86-85N/A
12/31/20211-26-81-81N/A
9/30/20211-85-75-75N/A
6/30/20212-71-57-57N/A
3/31/20211-69-54-54N/A
12/31/20201-67-56-56N/A
12/31/20196-85N/A-72N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HUMA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HUMA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HUMA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HUMA's revenue (62.3% per year) is forecast to grow faster than the US market (13% per year).

High Growth Revenue: HUMA's revenue (62.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if HUMA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/17 08:08
End of Day Share Price 2026/08/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Humacyte, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew MiksicBarclays
Bruce JacksonBenchmark Company
Michael GormanBTIG